Dr. Reddy's Laboratories Ltd receives EIR from USFDA for API facility at Bollaram

Dr. Reddy's Laboratories Limited had earlier announced about the inspection conducted by the United States Food & Drug Administration (USFDA) at its API manufacturing facility in Bollaram, Hyderabad (CTO 1). The Company has received the Establishment Inspection Report (EIR). The Agency has classified the inspection as Voluntary Action Indicated (VAI) and concluded that the inspection is "closed" under 21 CFR 20.64(d)(3).

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 5648.10 as compared to the previous close of Rs. 5656.75. The total number of shares traded during the day was 5527 in over 1173 trades.

The stock hit an intraday high of Rs. 5710.90 and intraday low of 5640.05. The net turnover during the day was Rs. 31347789.00.

Source : Equity Bulls

Keywords

DrReddysLaboratories INE089A01023 RDY USFDA EIR APIManufacturingFacility Bollaram Hyderabad